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Abstract: The objective of this study was to determine the in vitro antimicrobial activity of several
organic acids and their derivatives against Gram-positive (G+) and Gram-negative (G−) bacteria.
Butyric acid, valeric acid, monopropionin, monobutyrin, monovalerin, monolaurin, sodium formate,
and ProPhorce—a mixture of sodium formate and formic acid (40:60 w/v)—were tested at 8 to 16
concentrations from 10 to 50,000 mg/L. The tested bacteria included G− bacteria (Escherichia coli,
Salmonella enterica Typhimurium, and Campylobacter jejuni) and G+ bacteria (Enterococcus faecalis,
Clostridium perfringens, Streptococcus pneumoniae, and Streptococcus suis). Antimicrobial activity was
expressed as minimum inhibitory concentration (MIC) of tested compounds that prevented growth
of tested bacteria in treated culture broth. The MICs of butyric acid, valeric acid, and ProPhorce
varied among bacterial strains with the lowest MIC of 500–1000 mg/L on two strains of Campylobacter.
Sodium formate at highest tested concentrations (20,000 mg/L) did not inhibit the growth of Escherichia
coli, Salmonella Typhimurium, and Enterococcus faecalis, but sodium formate inhibited the growth of
other tested bacteria with MIC values from 2000 to 18,800 mg/L. The MIC values of monovalerin,
monolaurin, and monobutyrin ranged from 2500 to 15,000 mg/L in the majority of bacterial strains.
Monopropionin did not inhibit the growth of all tested bacteria, with the exception that the MIC of
monopropionin was 11,300 mg/L on Clostridia perfringens. Monolaurin strongly inhibited G+ bacteria,
with the MIC value of 10 mg/L against Streptococcus pneumoniae. The MIC tests indicated that organic
acids and their derivatives exhibit promising antimicrobial effects in vitro against G− and G+ bacteria
that are resistant to antimicrobial drugs. The acid forms had stronger in vitro antimicrobial activities
than ester forms, except that the medium chain fatty acid ester monolaurin exhibited strong inhibitory
effects on G+ bacteria.
Keywords: antimicrobial effects; Gram-negative bacteria; Gram-positive bacteria; minimum inhibitory
concentration; organic acids
1. Introduction
Antimicrobial drugs or antibiotics were discovered about a century ago and have been used widely
in human and animal medicine, as well as in animal production. Antimicrobial growth promoters are
antibiotics administered at low and subtherapeutic doses, which can enhance disease resistance and
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growth of animals [1,2]. However, there are growing concerns for the development of antimicrobial
resistance and the potential transmission of antibiotic resistance genes in bacteria from livestock
production to human beings. In the United States, therefore, the application of antibiotics as growth
promoters was completely banned in the livestock industry starting January 2017 [3]. The urgent need
for developing nutritional strategies or exploring bioactive compounds that may partially or completely
replace antibiotics as growth promoters for food-producing animals has remarkably increased in the
livestock industry.
Organic acids and salts of acids have been widely used in animal feed as acidifiers to modify
the intestinal environment as well as to enhance nutrient digestibility [4]. The most commonly used
acids include formic acid, citric acid, benzoic acid, carboxylic acids, and salts of short chain fatty acids
(SCFAs) [5,6]. Recently, combinations of organic acids and medium chain fatty acids (e.g., lauric acid)
have also demonstrated synergistic benefits on animal intestinal health and performance, compared
with the individual products [7]. In general, antimicrobial activity has been claimed or suggested as one
of the primary mechanisms of action through which organic acids could enhance animal health [8–10].
It is theorized that organic acids in their un-dissociated and uncharged state are capable of bypassing
bacterial cell membranes due to their lipophilic nature [11]. Upon entering the more alkaline interior
of a bacterium, the anion and proton from organic acids may have deleterious effects on the bacterium
by increasing osmotic stress and disrupting important biomolecule synthesis, which finally causes
bacterial death [12–14].
Although significant health benefits have been identified on SCFAs in vitro, direct addition of
them in animal feed is limited because of their pungent odor and unpalatable flavor [15,16]. Therefore,
SCFAs have been further processed as salt forms in combination with calcium or sodium, or as
esterified forms before addition to animal feed [17–19]. Naturally, these products are more stable
and/or pleasant compared with SCFAs [20]. An additional advantage of esterified SCFAs is that they
could escape gastric digestion before reaching the small intestine of animals [21]. Many other organic
acid derivatives require further investigation because they may exhibit antimicrobial activities and
therefore could be added to animal feed as alternatives to antibiotics. Thus, the objective of the current
study was to determine in vitro antimicrobial activity of several organic acids and their derivatives
against Gram-positive (G+) and Gram-negative (G−) bacteria that were specifically selected due to
their importance in the livestock industry.
2. Results
2.1. Organic Acids and Their Derivatives
All organic acids and their derivatives are liquid at ambient temperature, except for sodium formate
and monolaurin. The specific gravity of monopropionin, monobutyrin, monovalerin, butyric acid,
valeric acid, and ProPhorce were 1.30, 1.03, 1.01, 0.94, 0.92, and 1.36 g/mL, respectively. Monovalerin,
monobutyrin, monopropionin, and monolaurin are monoglycerides and are not water-soluble.
The chemical structures for individual organic acids and their derivatives are listed in Table 1.
2.2. Organic Acids and Their Derivatives Against G− Bacteria
The minimum inhibitory concentration (MIC) values of butyric acid against G− bacteria were 2300
or 2500 mg/L for Escherichia coli (E. coli; ATCC 25922 and F18) and Salmonella enterica Typhimurium
(S. Typhimurium; ATCC 14028 and ID# 4286) (Table 2). The lowest MIC values of butyric acid were
observed in Campylobacter jejuni (C. jejuni) with 500 mg/L for Campy 8DLIS D12-1 and 800 mg/L
for ATCC 33560, respectively. The MIC values of valeric acid and ProPhorce were approximately
2000 to 2800 mg/L against E. coli and S. Typhimurium strains, and 500 to 1000 mg/L against C. jejuni
(ATCC 33560) and C. jejuni (Campy 8DLIS D12-1), respectively. Sodium formate at the highest tested
concentrations (20,000 mg/L) did not inhibit the growth of E. coli or S. Typhimurium strains. However,
sodium formate inhibited the growth of both C. jejuni strains with a MIC value of 2000 mg/L.
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Table 1. Information of organic acids and their derivatives.
Compound Form ChemicalFormula Chemical Structure
Gravity,
g/mL Tested Concentration, mg/L
Butyric acid Liquid C4H8O2
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Table 1. Information of organic acids and their derivatives. 
Compound Form Chemical Formula Chemical Structure 
Gravity, 
g/mL 
Tested Concentration, 
mg/L 
Butyric acid Liquid C4 8 2 
   
0.94 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Valeric acid Liquid C5H10O2 
   
0.92 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Sodium 
formate Solid NaHCOO    
ND 2 
500, 1000, 2000, 4000, 8000, 
10,000, 12,500, 15,000, 
17,500, 20,000, 25,000 
ProPhorce 1 Liquid NaHCOO CH2O2 - 1.36 
10, 250, 500, 1000, 2000, 
4000, 8000, 10,000 
Monopropionin Liquid C6H12O4 
   
1.30 
500, 1000, 2000, 2500, 3000, 
3500, 5000, 7500, 10,000, 
25,000 
Monobutyrin Liquid C7H14O4 
   
1.03 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
50,000 
Monovalerin Liquid C8H16O4 
   
1.01 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
Monolaurin Solid C15H30O4 
  ND 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not 
detected due to the solid form. 
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on 
tested Gram-negative (G−) bacteria strains. 
 Escherichia coli 
Escherichi
a coli 
Salmonella 
enterica 
Typhimuriu
m 
Salmonella 
enterica 
Typhimuriu
m 
Campylobact
er jejuni 
Campylobact
er jejuni 
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 
Campy 8DLIS 
D12-1 
Butyric acid 2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
Valeric acid 2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
Sodium 
formate >20,000 >20,000 >20,000 >20,000 2000 (±0) 2000 (±0) 
ProPhorce 1 2000 (±0) 2200 (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
Monopropioni
n >10,000 >10,000 >10,000 ≥10,000 ≥10,000 >10,000
  
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 
a 10,000 (±0) 
Monovalerin 6700 (±2400) 5000 (±0) 
10,000 
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
Monolaurin 10,000 (±0) 10,000 (±0) 10,000 (±0) 10,000 (±0) 600 (±100) 5000 (±0) 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio; a no higher 
concentration was tested due to the elevated concentrations of ethanol. 
. 10, 250, 50 , 10 0, 200 , 2500,30 , 3500
Valeric acid Liquid C5H10O2
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Table 1. Information of organic acids and their derivatives. 
Compound Form Chemical Formula Chemical Structure 
Gravity, 
g/mL 
Tested Concentration, 
mg/L 
Butyric acid Liquid C4H8O  
   
0.94 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Valeric acid Liquid C5 10 2 
   
0.92 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Sodium 
formate Solid NaHCOO    
ND 2 
500, 1000, 2000, 4000, 8000, 
10,000, 12,500, 15,000, 
17,500, 20,000, 25,000 
ProPhorce 1 Liquid NaHCOO CH2O2 - 1.36 
10, 250, 500, 1000, 2000, 
4000, 8000, 10,000 
Monopropionin Liquid C6H12O4 
   
1.30 
500, 1000, 2000, 2500, 3000, 
3500, 5000, 7500, 10,000, 
25,000 
Monobutyrin Liquid C7H14O4 
   
1.03 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
50,000 
Monovalerin Liquid C8H16O4 
   
1.01 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
Monolaurin Solid C15H30O4 
  ND 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not 
detected due to the solid form. 
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on 
tested Gram-negative (G−) bacteria strains. 
 Escherichia coli 
Escherichi
a coli 
Salmonella 
enterica 
Typhimuriu
m 
Salmonella 
enterica 
Typhimuriu
m 
Campylobact
er jejuni 
Campylobact
er jejuni 
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 
Campy 8DLIS 
D12-1 
Butyric acid 2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
Valeric acid 2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
Sodium 
formate >20,000 >20,000 >20,000 >20,000 2000 (±0) 2000 (±0) 
ProPhorce 1 2000 (±0) 2200 (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
Monopropioni
n >10,000 >10,000 >10,000 ≥10,000 ≥10,000 >10,000
  
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 
a 10,000 (±0) 
Monovalerin 6700 (±2400) 5000 (±0) 
10,000 
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
Monolaurin 10,000 (±0) 10,000 (±0) 10,000 (±0) 10,000 (±0) 600 (±100) 5000 (±0) 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio; a no higher 
concentration was tested due to the elevated concentrations of ethanol. 
. 10, 250, 50 , 1000, 2 , 2500,30 , 3500
Sodium
formate Solid a C
2
D 2
500, 1000, 2000, 4000, 8000,
10,000, 12,500, 15,000, 17,500,
20,000, 25,000
ProPhorce 1 Liquid C 2 2
. 10, 250, 50 , 1000, 2 , 4000,80 , 10,000
Mon propioni Liquid C6 12 4
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a le 1. I f r ati  f r a ic aci s a  t eir eri ati es. 
 r  e ical r la e ical tr ct re 
ra it , 
/  
este  ce trati , 
/  
t ric aci  i i  4 8  
   
0.94 10, 250, 500, 1000, 2 0, 2500, 3000, 3500 
aleric aci  i i  5 10 2 
   
0.92 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
S i  
f r ate S li  a     
 2 
500, 1000, 2000, 4000, 8000, 
10,000, 12,500, 15,000, 
17,500, 20,000, 25,000 
r rce 1 i i  a  
2 2 - 1.36 
10, 250, 500, 1000, 2000, 
4000, 8000, 10,000 
r i i  i i  6 12 4 
   
1.30 
500, 1000, 2000, 2500, 3000, 
3500, 5000, 7500, 10,000, 
25,000 
t ri  i i  7 14 4 
   
1.03 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
50,000 
aleri  i i  8 16 4 
   
1.01 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
la ri  S li  15 30 4 
   
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
1 r rce is a ixt re f s i  f r ate a  free f r ic aci  it  40:60 f /v rati . 2 : t 
etecte  e t  t e s li  f r . 
a le 2. i i  i i it r  c ce trati s ( / ) (±S ) f r a ic aci s a  t eir eri ati es  
teste  ra - e ati e ( −) acteria strai s. 
 sc eric i c li 
sc eric i
 c li 
l ell  
e teric  
i ri
 
l ell  
e teric  
i ri
 
l b ct
er jej i 
l b ct
er jej i 
  25922 18  14028 I # 4286  33560 
a  8 IS 
12-1 
t ric aci  2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
aleric aci  2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
S i  
f r ate >20,000 >20,000 >20,000 >20,000 2000 (±0) 2000 (±0) 
r rce 1 2000 (±0) 2200 (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
r i i
 >10,000 >10,000 >10,000 ≥10,000 ≥10,000 >10,000
  
t ri  15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 
a 10,000 (±0) 
aleri  6700 (±2400) 5000 (±0) 
10,000 
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
la ri  10,000 (±0) 10,000 (±0) 10,000 (±0) 10,000 (±0) 600 (±100) 5000 (±0) 
1 r rce is a ixt re f s i  f r ate a  free f r ic aci  it  40:60 f /v rati ; a  i er 
c ce trati  as teste  e t  t e ele ate  c ce trati s f et a l. 
. 500, 1000, 2000, 2500, 3000,3500, 5000, 7500, 10,000, 25,000
Monobutyrin Liquid C7H14O4
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Table 1. Infor ation of organic acids and their derivatives. 
Compound Form Che ical Formula Che ic  r  
ra it , 
g/ L 
Tested Concentration, 
mg/L 
Butyric acid Liquid C4H8O2 
   
0.94 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Valeric acid Liquid C5H10O2 
   
0.92 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Sodium 
for ate Solid NaHCOO    
ND 2 
500, 1000, 2000, 4000, 8000, 
1 ,000, 12,5 , 15, 0, 
17,500, 2 , 00, 25, 00 
ProPhorce 1 Liquid NaHCOO CH2O2 - 1.36 
10, 250, 5 , 1000, 2 00, 
4000, 8000, 10,000 
Monopropionin Liquid C6H12O4 
   
1.30 
500, 1000, 2000, 2500, 3000, 
3500, 5000, 7500, 10,000, 
25,000 
M nobutyrin Liquid C7H14 4 
   
1.03 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
50,000 
Monovalerin Liquid C8H16O4 
   
1.01 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
Monolaurin Solid C15H30O4 
  ND 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not 
detected due to the solid form. 
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on 
tested Gram-negative (G−) bacteria strains. 
 Escherichia coli 
Escherichi
a coli 
Salmonella 
enterica 
Typhimuriu
m 
Salmonella 
enterica 
Typhimuriu
m 
Campylobact
er jejuni 
Campylobact
er jejuni 
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 
Campy 8DLIS 
D12-1 
Butyric acid 2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
Valeric acid 2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
Sodium 
formate >20,000 >20,000 >20,000 >20,000 2000 (±0) 2000 (±0) 
ProPhorce 1 2000 (±0) 2200 (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
Monopropioni
n >10,000 >10,000 >10,000 ≥10,000 ≥10,000 >10,000
  
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 
a 10,000 (±0) 
Monovalerin 6700 (±2400) 5000 (±0) 
10,000 
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
Monolaurin 10,000 (±0) 10,000 (±0) 10,000 (±0) 10,000 (±0) 600 (±100) 5000 (±0) 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio; a no higher 
concentration was tested due to the elevated concentrations of ethanol. 
1.03
10, 250, 50 , 1000, 2500,
30 0, 35 0, 0, 10,000,
15,00 , 20,000, 25, , 30,000,
40, , 50,0
Monovalerin Liquid C8H16O4
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Table 1. Information of organic acids and their derivatives. 
Compound Form Chemical For ul  Chemical Structure 
G avity, 
g/mL 
Tested Concentration, 
mg/L 
Butyric acid Liquid C4H8O2 
   
0.94 10, 250, 500, 1000, 2000, 0, 3 00, 3500 
Valeric acid Liquid C5H10O2 
   
0.92 10, 250, 500, 1000, 2000, 0, 3 00, 3500 
Sodium 
formate Solid NaHCOO    
ND 2 
500, 100 , 20 , 400 , 8000, 
10,000, 12,5 0, 15,000, 
7 5 20 00, 2  
ProPhorce 1 Liquid NaH OO C 2O2 - 1.36 
10, 2 , 500  1000, 20 , 
400 , 8000, 1 ,000 
Monopropionin Liquid C6H12O4 
   
1.30 
500, 1000, 2000, 250 , 3000, 
3500, 5 00, 7500, 1 000, 
25,00  
Monobutyrin Liquid C7H14O4 
   
1.03 
10, 250, 500  1000, 2000, 
2500, 300 , 35 , 50 , 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
5  
M novalerin Liquid C8 16 4 
   
1.01 
10, 250, 50  1000, 2000, 
2500, 300 , 35 , 50 , 
10,000, 15,000, 20,000, 
2  
Monolaurin Solid C15H30O4 
  ND 
10, 250, 500  1000, 2000, 
2500, 300 , 35 , 50 , 
10,000, 15,000, 20,000, 
2 ,  
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not 
detected due to the solid f rm. 
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on 
tested Gram-negative (G−) bacteria strains. 
 Escherichia coli 
Escherichi
a coli 
Salmonella 
enterica 
Typhimuriu
m 
Salmonella 
enterica 
Typhimuriu
m 
Campylobact
er jejuni 
Campylobact
er jejuni 
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 
Campy 8DLIS 
D12-1 
Butyric acid 300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
Valeric acid 2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
Sodium 
formate >20, 0 >20, 0 >20,000 >20,000 2000 (±0) 2000 (±0) 
ProPhorce 1 2000 (±0) 2  (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
Monopropioni
n >10,000 >10, 0 >10,000 ≥10,000 ≥10,000 >10,000
  
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 
a 10,000 (±0) 
Monovalerin 67 0 (±24 ) 5000 (±0) 
10,0  
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
o ol urin 10,000 (±0) 10, 0 (±0) 10,00  (±0) 0 6 0 ) 5 0 (± ) 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio; a no higher 
concentration was tested due to the elevated concentrations of ethanol. 
.
10, 250, 50 , 1 00, 2000, 2500,
3000, 3500, 5 0, 1 ,000,
15 000, 20,0 , 25, 00
Monolaurin Solid C15H30O4
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Table 1. Information of organic acids and their derivatives. 
Compound Form Chemical Formula Chemical Structure 
Gravity, 
g/mL 
Tested Concentration, 
mg/L 
Butyric acid Liquid C4H8O2 
   
0.94 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Valeric acid Liquid C5 10O2 
   
0.92 10, 250, 500, 1000, 2000, 2500, 3000, 3500 
Sodium 
formate Sol NaHCOO    
ND 2 
500, 1000, 2000, 4000, 8000, 
10,000, 12,500, 15,000, 
17,500, 20,000, 25,000 
ProPhorce 1 Liquid a COO CH2 2 - 1.36 
10, 250, 500, 1000, 2000, 
4000, 8000, 10,000 
Monopropionin Liquid C6 12O4 
   
1.30 
500, 1000, 2000, 2500, 3000, 
3500, 5000, 7500, 10,000, 
25,000 
Monobutyrin Liquid C7H14O4 
   
1.03 
1  25 , 500, 1000, 2 00, 
250 , 3000, 3500, 5 0, 
10,000, 15,000, 20,000, 
25,000, 30,000, 40,000, 
50,000 
Monovalerin Liquid C8H16O4 
   
1.01 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
Monolaurin Solid C15H30O4 
  ND 
10, 250, 500, 1000, 2000, 
2500, 3000, 3500, 5000, 
10,000, 15,000, 20,000, 
25,000 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not 
detected due to the solid form. 
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on 
tested Gram-negative (G−) bacteria strains. 
 Escherichia coli 
Escherichi
a coli 
Salmonella 
enterica 
Typhimuriu
 
Salmonella 
enterica 
Typhimuriu
 
Campylobact
er jejuni 
Campylobact
er jejuni 
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 
Campy 8DLIS 
D12-1 
Butyric acid 2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0) 
Valeric acid 2700 (±400) 
2800 
(±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300) 
Sodium 
form te >20, 00 >20, 00 >20,000 >20,000 2000 (±0) 2000 (±0) 
Pr Phorce 1 2000 (±0) 2200 (±700) 2200 (±700) 2200 (±700) 700 (±300) 1000 (±0) 
Monopropioni
n >10,000 >10, 00 >10,000 ≥10,000 ≥10,000 >10,000
  
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±24 ) 10,000 (±0) >50,000 
a 10,000 (±0) 
onovalerin 6700 (±2400) 5000 (±0) 
10,000 
(±5000) 15,000 (±0) 2500 (±1300) 3700 (±900) 
Monolaurin 10,000 (±0) 10,000 (±0) 10,000 (±0) 10,000 (±0) 600 (±100) 5000 (±0) 
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio; a no higher 
c ncentration was tested due to the elevated concentrations of ethanol. 
ND
10, 25 , 500, 1000, 2000, 2500,
3000, 3500, 5000, 10,000,
15, 00, 20, 5,000
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio. 2 ND: not detected due to
the solid form.
Table 2. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on
tested Gram- egative (G−) bacteria strains.
Escher chia
coli
Escherichia
coli
Salmonella
enterica
Typhimurium
Salmo ell
enterica
Typhimurium
Campylobacter
jejuni
Campylobacter
jejuni
Compound ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 Campy 8DLISD12-1
Butyric acid 2300 (±250) 2500 (±0) 2500 (±0) 2300 (±250) 800 (±300) 500 (±0)
Valeric acid 2700 (±400) 2800 (±400) 2700 (±300) 2600 (±200) 500 (±0) 700 (±300)
Sodium form te >20,000 >2 ,00 >20,000 >20,0 0 2000 (±0) 200 (±0)
ProPhorce 1 2000 (±0) 2 ( 700) 22 0 (±700) 2200 (±700) 700 (±300) 1000 (±0)
Monopropionin >10, 0 >10,0 0 >10, 00 ≥10,0 0 ≥10, 00 >1 ,000
Monobutyrin 15,000 (±0) 10,000 (±0) 11,700 (±2400) 10,000 (±0) >50,000 a 10,000 (±0)
Monovalerin 6700 (±2400) 5000 (±0) 10,000 (±5000) 15,000 (±0) 2500 (±1300) 3700 (±900)
Monolaurin 10,000 (±0) 10,000 (±0) 1 ,000 (±0) 10,00 (±0) 600 (±100) 5000 (±0)
1 ProPhorce is a mixture of sodium formate and free formic acid with 4 :60 of w/v ratio; a no higher concentration
was tested due to the elevated concentrations of ethanol.
Monobutyrin did not inhibit C. jejuni (ATCC 33560) even at the highest concentration of 50,000 mg/L.
The IC values of monobutyrin against other G− bacteria were between 1 ,000 and 5, 0 mg/L.
Monopropionin at 10,00 mg/L inhibited the growth of G− bacteria tested in the assays. Monovalerin
had IC values of 67 and 50 mg/L against E. coli strains, 10,000 and 15,000 mg/L against S.
Typhimurium strains, and 2500 and 3700 mg/L against C. jejuni strains. Monolaurin had a MIC value of
10,000 mg/L against all E. coli and S. Typhimurium strains, and 5000 mg/L against C. jejuni (Campy8DLIS
D12-1). The lowest MIC value of monolaurin was 600 mg/L against C. jejuni (ATCC 33 60).
Antimicrobial susceptibility to c mmon antimicrobial rugs of tested G− bacterial strains are
shown in Table 3. Both reference and wild strains of E. coli and Salmonella were resista t to m ltiple
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drugs (i.e., ≥3 drugs). With the limited available MIC interpretive criteria, the susceptibility of
Campylobacter to tested drugs was mostly undermined. However, both strains were resistant to
ciprofloxacin, gentamicin, and tetracycline.
2.3. Organic Acids and Their Derivatives Against G+ Bacteria
The MIC values of butyric acid and valeric acid were both 2000 mg/L for Enterococcus faecalis
(E. faecalis), 1200 and 1300 mg/L for Clostridium perfringens (C. perfringens), 700 and 1000 mg/L for
Streptococcus pneumoniae (S. pneumoniae), and 700 and 1000 mg/L for Streptococcus suis (S. suis; Table 4).
The MIC values of sodium formate were 11,000 to 18,800 mg/L against C. perfringens and two
Streptococcus strains, but 20,000 mg/L sodium formate did not inhibit the growth of E. faecalis. The MIC
values of ProPhorce were 1000 mg/L against E. faecalis, C. perfringens, or S. pneumoniae, and 1900 mg/L
against S. suis.
Monobutyrin and monovalerin had similar antimicrobial activities on G+ bacteria. The MIC values
of monobutyrin and monovalerin were 10,000 and 10,000 mg/L for E. faecalis, 2600 and 3100 mg/L for C.
perfringens, 7700 and 2400 mg/L for S. pneumoniae, and 7800 and 2000 mg/L for S. suis. Monopropionin
at the highest tested concentrations (25,000 mg/L) did not inhibit the growth of two Streptococcus strains.
However, monopropionin inhibited the growth of E. faecalis and C. perfringens with MIC values of
10,000 and 11,300 mg/L, respectively. The MIC values of monolaurin were 500 mg/L for E. faecalis,
300 mg/L for C. perfringens, 10 mg/L for S. pneumoniae, and 400 mg/L for S. suis.
Susceptibility to commonly used antimicrobial drugs of tested G+ bacteria strains are shown in
Table 5. E. faecalis (ATCC 29212) exhibited broad resistance to most tested antimicrobial drugs in this
trial. With the available MIC interpretive criteria, C. perfringens (ATCC 12915) was determined resistant
to tetracycline, chloramphenicol, and penicillin. The two strains of Streptococcus were either resistant
(R) (S. pneumoniae) or intermediate resistant (IR) (S. suis) to tetracycline.
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Table 3. Antimicrobial susceptibility of tested G- bacteria strains.
Antimicrobial Drug
Range of
Concentrations
(mg/L)
Escherichia
coli
Escherichia
coli
Salmonella
enterica
Typhimurium
Salmonella
enterica
Typhimurium
Campylobacter
jejuni Campylobacter jejuni
ATCC 25922 F18 ATCC 14028 ID# 4286 ATCC 33560 Campy 8DLIS D12-1
Amikacin 8–32 ORC S ORC ORC NA NA
Piperacillin/tazobactam constant
4 8/4–128/4 R S R R NA NA
Tigecycline 1–8 NA NA NA NA NA NA
Ticarcillin/clavulanic acid
constant 2 8/2–64/2 IR S ORC IR NA NA
Levofloxacin 1–8 R R R R NA NA
Nitrofurantoin 32–64 ORC S ORC ORC NA NA
Tetracycline 4–8 ORC ORC ORC ORC R R
Doripenem 0.5–4 R S R R NA NA
Minocycline 1–8 ORC IR ORC ORC NA NA
Ertapenem 0.25–8 R IR R R NA NA
Trimethoprim/sulfamethoxazole 2/38–4/76 R R R R NA NA
Imipenem 0.5–8 R IR R R NA NA
Piperacillin 16–64 ORC IR ORC ORC NA NA
Meropenem 0.5–8 R S R R NA NA
Gentamicin 2–8 ORC S ORC ORC R R
Cefazolin 1–16 R R R R NA NA
Tobramycin 2–8 ORC S ORC ORC NA NA
Ceftazidime 1–16 R R R R NA NA
Ampicillin/sulbactam 2:1 ratio 4/2–16/8 ORC IR ORC IR NA NA
Aztreonam 1–16 NA NA NA NA NA NA
Ampicillin 8–16 ORC ORC ORC IR NA NA
Cefepime 4–32 R SSD R R NA NA
Ciprofloxacin 0.5–2 ORC S R R R R
Ceftriaxone 0.5–32 R R R R NA NA
S: susceptible; SSD: susceptible-dose dependent; IR: intermediate resistant; R: resistant; ORC: out range of concentration; NA: no interpretative criteria for this bacterium/antimicrobial
combination currently available.
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Table 4. Minimum inhibitory concentrations (mg/L) (±SD) of organic acids and their derivatives on
tested Gram-positive (G+) bacteria strains.
Enterococcus faecalis Clostridiumperfringens
Streptococcus
pneumoniae Streptococcus suis
Compound ATCC 29212 ATCC 12915 ATCC 49619 ATCC 43765
Butyric acid 2000 (±0) 1200 (±400) 1000 (±0) 700 (±2400)
Valeric acid 2000 (±0) 1300 (±700) 1000 (±0) 1000 (±0)
Sodium formate >20,000 18,800 (±7100) 15,800 (±24,00) 11,000 (±7100)
ProPhorce 1 1000 (±0) 1000 (±0) 1000 (±0) 1900 (±3400)
Monopropionin >10,000 11,300 (±6400) >25,000 >25,000
Monobutyrin 10,000 (±0) 2600 (±1300) 7700 (±2900) 7800 (±2500)
Monovalerin 10,000 (±0) 3100 (±1200) 2400 (±400) 2000 (±700)
Monolaurin 500 (±0) 300 (±400) 10 (±0) 400 (±800)
1 ProPhorce is a mixture of sodium formate and free formic acid with 40:60 of w/v ratio.
Table 5. Antimicrobial susceptibility of tested G+ bacteria strains.
Antimicrobial Drugs
Range of
Concentrations
(mg/L)
Enterococcus
faecalis
Clostridium
perfringens
Streptococcus
pneumoniae
Streptococcus
suis
ATCC 29212 ATCC 12915 ATCC 49619 ATCC 43765
Tigecycline 0.015–0.5 NA NA NA NA
Erythromycin 0.25–8 IR NA S S
Tetracycline 1–32 R R R IR
Ciprofloxacin 0.12–4 R NA NA NA
Chloramphenicol 2–32 R R S S
Penicillin 0.25–16 R R NA ORC
Daptomycin 0.25–16 NA NA S S
Vancomycin 0.25–32 R NA S S
Streptomycin 512–2048 R NA NA NA
Nitrofurantoin 2–64 ORC NA NA NA
Tylosin tartrate 0.25–32 R NA NA NA
Gentamicin 128–1024 R NA NA NA
Quinupristin/dalfopristin 0.5–32 R NA S S
Lincomycin 1–8 S NA NA NA
Linezolid 0.5–8 R NA S S
Kanamycin 128–1024 R NA NA NA
S: susceptible; IR: intermediate resistant; R: resistant; ORC: out range of concentration; NA: no interpretative criteria
for this bacterium/antimicrobial combination currently available.
3. Discussion
Results in the current study indicated that butyric acid, valeric acid, and ProPhorce (the mixture of
sodium formate and free formic acid, 40:60 w/v) had the strongest in vitro antimicrobial effects against
E. coli and Salmonella strains, followed by the monoglycerides of SCFAs and lauric acid. However,
sodium formate did not exhibit inhibitory effects on E. coli and Salmonella strains at the highest
tested doses. Different trends were detected in the antimicrobial activities of the tested compounds
against Campylobacter strains, as follows: butyric acid, valeric acid, and ProPhorce > sodium formate,
monovalerin, monolaurin > monopropionin and monobutyrin. In addition, the strongest antimicrobial
activities against G+ bacteria were observed in monolaurin, ProPhorce, butyric acid, and valeric acid.
The weakest antimicrobial activities against G+ bacteria were observed in monopropionin and sodium
formate, whereas monovalerin and monobutyrin were in the middle.
Short-chain fatty acids are fatty acids with a chain of less than six carbon atoms, which are
primarily produced by hindgut fermentation of dietary fiber [22]. Propionic acid and butyric acid
produced in the gastrointestinal tract of animals are considered particularly important metabolites that
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have antimicrobial effects on pathogenic bacteria [22,23]. The antimicrobial activities of butyric acid
have been widely reported in previously published research to effectively inhibit G− and G+ bacteria,
such as commensal E. coli, Klebsiella pneumoniae, S. Typhimurium, and C. perfringens [8,9,14,24,25]. It
has been also reported that the valeric acid-producing bacteria Oscillibacter valericigenes were more
abundant in the fecal samples of healthy people than people with Crohn’s disease [26], indicating
valeric acid may also benefit intestinal health. Results in the current study suggest that valeric acid has
similar antimicrobial activity against G− and G+ bacteria in comparison to butyric acid. The mode of
action is likely due to the ability of these acids to penetrate bacterial cell membrane and to acidify cell
cytoplasm, thus inhibiting bacterial growth [12–14]. Other mechanisms have been also proposed that
organic acids could reduce ATP production by uncoupling electron transport, or they could interrupt
nutrient uptake by disturbing bacterial cell membrane [11,27,28].
The present study also observed that ProPhorce exhibited stronger antimicrobial activities against
G− and G+ bacteria compared with sodium formate. ProPhorce is a mixture of sodium formate and
formic acid; therefore, current results indicate that formic acid likely has stronger in vitro antimicrobial
activity than sodium formate. To that end, formic acid is the major component responsible for
antimicrobial effects of ProPhorce in vitro. These results were not surprising because the antimicrobial
activity of formic acid has been confirmed and widely reported against a broad range of bacterial
strains, including E. coli, S. Typhimurium, Campylobacter strains, and S. mutans in previously published
research [29–32]. Formic acid is a colorless liquid with pungent odor that has been commonly used in
animal feed as an organic acidifier [6,33,34]. However, results from the current study suggest sodium
formate has very limited antimicrobial activity in vitro.
Monoglycerides of SCFAs have several remarkable advantages compared with free SCFAs.
They are more stable and have a less stringent odor compared with free SCFAs, increasing their
potential as alternatives to antibiotics in animal feed. In addition, the ester forms of organic acids
are digested and absorbed as lipids, which ensures they pass the low-pH stomach and successfully
deliver their antimicrobial effects to the small intestine of animals. In the current study, monobutyrin
and monovalerin exhibited comparable inhibitory effects on G− and G+ bacteria, although their
antimicrobial activities were not as strong as their acid forms. However, monopropionin has weaker
antimicrobial activities against G− and G+ bacteria compared with monobutyrin and monovalerin.
Results of the present study were consistent with previously published research that indicated
monobutyrin had antimicrobial effects on many E. coli strains, S. Typhimurium, and C. perfringens
strains in vitro [25,35].
Medium chain fatty acids have recently attracted increased attention due to their potential
antimicrobial activities and their potential ability to suppress the development of antibiotic-resistant
genes in bacteria [21,36,37]. Lauric acid is a C12 fatty acid and has been indicated to have the strongest
antimicrobial activity compared with other medium chain fatty acids [38–40]. Although Schlievert
and Peterson [41] reported several G− bacteria, including Salmonella and E. coli strains, were not
susceptible to monolaurin, results of the present study suggest monolaurin has similar or even
stronger antimicrobial activity against E. coli, S. Typhimurium, and C. jejuni strains compared with
monobutyrin. This could be due to different bacterial strains that have different susceptibility.
These observations are consistent with a study reported by Anacarso et al. [35], in which 37 E. coli
strains were highly susceptible to a blend containing monolaurin and monobutyrin, although the
antimicrobial activity was not tested with individual monoglycerides in this study. In agreement with
previously published research [35,41,42], the present study demonstrated that G+ bacteria were more
susceptible to monolaurin than G− bacteria, with MIC values from 10 to 500 mg/L against G+ bacteria
and MIC values from 600 to 10,000 mg/L against G− bacteria. It has also been reported that monolaurin
actively inhibited the growth of Staphylococcus, Streptococcus, Bacillus, and several other G+ bacterial
strains with relatively low MIC values [37,43]. As discussed above, the antimicrobial activities of
fatty acids and their derivatives are mainly due to the disruption of bacterial cell membranes and the
subsequent cell disorganization. However, the ability of medium chain fatty acids to disrupt cellular
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membranes has been demonstrated to vary among bacterial strains. This variation in susceptibility is
likely due to the different outer membranes of the bacteria. For instance, G+ bacteria have cell walls
composed of thick layers of peptidoglycan, whereas G− bacteria have a thin layer of peptidoglycan
and an outer membrane that is primarily composed of lipopolysaccharides and proteins [40,44].
The O-side chains of lipopolysaccharides comprise an effective barrier for hydrophilic molecules, such
as lipids [40,45]. In addition, these lipopolysaccharides are strongly connected, which makes it difficult
for molecules to penetrate the outer membranes. This could be the reason that G− bacteria were less
susceptible to monolaurin than G+ bacteria in the present study. The outer membrane of Campylobacter
species expresses lipooligosaccharides that lack the O-side chain [46]; therefore, they are also more
susceptible to monolaurin compared with E. coli and S. Typhimurium. Other mechanisms have been
suggested for the antimicrobial effects of monolaurin on G+ bacteria, including the disturbance of
toxin and exo-protein production at the transcriptional level or the regulation of bacterial signaling
pathways that are critical for bacterial survival [37,41,47].
With the purpose of understanding antimicrobial susceptibility of bacterial strains in this study,
the MIC values of antimicrobial drugs were also tested on the same strains of bacteria. All tested
strains of E. coli and Salmonella exhibited multidrug resistance (i.e., resistant to ≥3 drugs). With the
limited available MIC interpretive criteria, both strains of Campylobacter were determined resistant
to ciprofloxacin, gentamicin, and tetracycline. The development of resistance to commonly used
antibiotics by G− bacteria has gained increasing concern. For example, in 2012, the United States
Department of Agriculture (USDA)’s national animal health monitoring system (NAHMS) isolated
1614 E. coli strains from swine production sites in 13 states that represented 91% of the U.S. pig inventory.
Almost all E. coli isolated from swine (91.2%) were resistant to tetracycline (an antimicrobial drug
used to treat pneumonia, certain skin infections, etc.), and more than one-third of the isolated E. coli
were resistant to sulfisoxazole, a common sulfa antibiotic [48]. Interestingly, F18 E. coli, one of the
most dominant types of pathogenic E. coli causing post-weaning diarrhea in piglets, was shown in
this study to be susceptible in vitro to the organic acids and their derivatives, although the strain was
determined resistant and intermediate resistant to multiple antimicrobial drugs. Post-weaning diarrhea
accounts for 20–30% of cases of mortality in weanling pigs, causing huge economic loss in the pig
industry [49,50]. Results of the present study suggest organic acid derivatives could be supplemented
as antibiotic alternatives to prevent or control post-weaning diarrhea caused by F18 E. coli infection.
In regard to antimicrobial susceptibility of the tested G+ bacterial strains, broad resistance in
Enterococcus, multidrug resistance in C. perfringens, and resistance to at least one drug in Streptococcus
were observed in the present study. Interestingly, monolaurin at relatively low concentrations in our
study inhibited the in vitro growth of these antimicrobial resistant pathogens. Taking C. perfringens as
an example, this bacterial species is one of the most common foodborne pathogens in humans, and is
also responsible for severe infections in animals, especially in poultry [33,51]. C. perfringens-induced
necrotic enteritis may cause sudden death of broiler chickens, with mortality rates of up to 50% [52–54].
Subclinical C. perfringens infection also contributes to huge economic loss due to poor performance and
high cost of medication and maintenance [55]. Although organic acids (i.e., formic acid, butyric acid,
etc.) have been widely reported to control necrotic enteritis and to promote performance of chickens,
the utilization of their derivatives are limited [33,56]. In summary, our results showed promising
in vitro antimicrobial effects of tested organic acids and their derivatives against tested bacterial strains
that are resistant to commonly used antimicrobial drugs. In vivo animal trials are needed to evaluate
the efficacy of organic acid derivatives on animal health, such as in pigs and poultry.
4. Materials and Methods
4.1. Organic Acids and Their Derivatives
In vitro assays of antimicrobial activity against G− and G+ bacteria were performed on
monopropionin, monobutyrin, monovalerin, monolaurin, butyric acid, valeric acid, sodium formate,
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and ProPhorce (a mixture of sodium formate and free formic acid with 40:60 w/v). All tested compounds
were provided by Perstorp Waspik BV (Waspik, The Netherlands). Butyric acid, valeric acid, sodium
formate, and ProPhorce are water-soluble and were directly mixed into culture broth at different
tested concentrations based on previously published research [25,40] and industry recommendation.
Monovalerin, monobutyrin, monopropionin, and monolaurin are not water-soluble. These compounds
were first dissolved into ethanol prior to mixing into culture broth. The working concentrations (v/v)
of ethanol in culture broth were optimized as 0.5% for monopropionin, 10% for monovalerin and
monolaurin, and 20% for monobutyrin. The tested concentrations for individual organic acids and
their derivatives are listed in Table 1.
4.2. Tested Bacterial Strains
Six G− bacterial strains and four G+ bacterial strains were used in these in vitro assays (Table 6).
Among these bacterial strains, E. coli ATCC 25922 and E. faecalis ATCC 29212 are reference strains
recommended by Clinical and Laboratory Standards Institute (CLSI) for antimicrobial susceptibility
testing. These two strains and C. jejuni ATCC 33560 are also recommended as control strains for
antimicrobial susceptibility testing by the European Committee on Antimicrobial Susceptibility Testing
(EUCAST). C. perfringens ATCC 12915 is a control strain recommended by the British Society for
Antimicrobial Chemotherapy (BSAC) for antimicrobial susceptibility testing. S. pneumoniae ATCC
49619 is a reference strain recommended by the EUCAST, the CLSI, and the BSAC. S. Typhimurium
(ATCC 14028) has been used in control culture, media testing, preparatory test control, enteric research,
emerging infectious disease research, pharmaceutical and personal care, and water testing according
to the information from the American Type Culture Collection (ATCC).
Table 6. Information of tested bacterial strains.
Species Strain Designation Gram Stain Strain Type
Escherichia coli ATCC 25922 G− reference
Escherichia coli F18 G− wild
Salmonella enterica Typhimurium ATCC 14028 G− reference
Salmonella enterica Typhimurium Sample ID #4286 G− wild
Campylobacter jejuni ATCC 33560 (CIP 702) G− reference
Campylobacter jejuni Campy 8DLIS D12-1 G− wild
Enterococcus faecalis ATCC 29212 G+ reference
Clostridium perfringens ATCC 12915 G+ reference
Streptococcus pneumoniae ATCC 49619 G+ reference
Streptococcus suis ATCC 43765 G+ wild
S. suis ATCC 43765 is a strain isolated from pigs. The E. coli F18 strain is a pathogenic strain
originally isolated from a field disease outbreak by the University of Illinois Veterinary Diagnostic
Lab (isolate number: U.IL-VDL # 05-27242). S. Typhimurium (ID #4286) is a wild strain isolated from
a cull dairy cow in California. Campylobacter (Campy 8DLIS D12-1) is a wild strain isolated from
environmental water in California.
4.3. MIC Assays of G- Bacteria
The minimum inhibitory concentration (MIC) of individual organic acids against different bacterial
strains was tested in triplicates using micro-broth dilution method [57–59]. For E. coli and Salmonella
strains, four to five well-isolated fresh colonies were used to inoculate 2 mL brain heart infusion (BHI)
broth and then incubated at 37 ◦C without CO2 for 2–6 h. The broth cultures were added dropwise to
0.85% NaCl to achieve a turbidity equivalent to a 0.5 McFarland nephelometer standard. Next, 10 µL
of this bacterial solution was added to 40 µL cation-adjusted Mueller–Hinton broth and inoculated
into 96-well plates containing serially diluted tested organic acids. Plates were then incubated at 37 ◦C
without CO2 for 18–24 h. Campylobacter strains were retrieved by streaking on Trypticase soy agar with
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5% sheep’s blood and incubating in a jar (Pack-Rectangular Jar, MGC, NY, USA) at 42 ◦C with Campy
sachets (GasPak EZ Campy container System, BD, MD, USA). Fresh colonies were inoculated into
BHI broth to prepare bacterial solutions and to perform the MIC assays in the same way as described
above, except that the plates were incubated in a jar at 42 ◦C with Campy sachets for 18–24 h. E. coli
ATCC 25922 was included in all assays testing G− bacteria. Culture broth without ethanol was used
as medium control. Ethanol at designated concentrations equivalent to working concentrations in
treated culture broth was used as solvent control. Medium control and solvent control were included
for each bacterial strain in all assays. The MIC values were determined for individual organic acids
and their derivatives as the minimum concentration that inhibits visible growth (e.g., turbidities,
sediments) of bacteria. The MIC values were expressed as arithmetic means of triplicate tests and
standard deviation (SD).
4.4. MIC Assays of G+ Bacteria
For C. perfringens, S. suis, and S. pneumoniae strains, bacterial solutions were prepared and MIC
assays were performed using the same procedures as described above, except for the incubation
conditions. Specifically, C. perfringens was incubated in a pouch (GasPak EZ Campy Gas Generating
Pouch System, BD Diagnostics, Sparks, MD, USA) at 37 ◦C with anaerobic sachets (Anaero Pouch
System, Mitsubishi Gas Chemical America, Inc. New York, NY, USA) for 18–24 h. S. pneumoniae was
incubated in a pouch at 37 ◦C with Campy sachets for 18–24 h. S. suis was incubated at 37 ◦C without
CO2 for 24 h. The E. faecalis ATCC 29212 was included in all assays testing G+ bacteria. Medium control
and solvent control were included in all assays as well. The MIC values were determined for each
organic acid as the minimum concentration that inhibits visible growth (e.g., turbidities, sediments)
of bacteria.
4.5. Assay of Bacterial Susceptibility to Antimicrobial Drugs
Antimicrobial susceptibility of G− bacterial strains was tested against 24 antimicrobial drugs, and
that of G+ bacterial strains was tested against 16 antimicrobial drugs, independently. These drugs
represent current commonly used drugs in human and veterinary medicine based on the panel
of antimicrobials of the National Antimicrobial Resistance Monitoring System (NARMS) tests
(Tables 2 and 4). Sensititre Gram-negative plate GN4F (G−) and Sensititre Gram-positive NARMS plate
CMV3AGPF (G+) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The procedures
for testing MIC of antimicrobial drugs followed the standard instructions provided in the plates and
used same MIC methods as described above. Interpretation of the susceptibility of E. coli, Salmonella,
Enterococcus, Clostridium, and Streptococcus was based on CLSI criteria [60]. Interpretation of the
susceptibility of Campylobacter was based on the criteria for susceptibility testing used by Centers for
Disease Control and Prevention (CDC) NARMS (https://www.cdc.gov/narms/antibiotics-tested.html).
5. Conclusions
Organic acids and their derivatives exhibited promising antimicrobial effects against both G−
and G+ bacteria that were resistant to antimicrobial drugs in the current study. The order of
overall antimicrobial strength, in descending order, was butyric acid, valeric acid, and formic acid >
monovalerin, monolaurin, and monobutyrin > monopropionin and sodium formate. Specifically,
SCFAs and formic acid were the most promising inhibitors of G− bacteria. G+ bacteria were highly
susceptible to monolaurin at the concentration of 10 mg/L, and were also susceptible to SCFAs,
formic acid, monobutyrin, and monovalerin. These compounds with promising in vitro antimicrobial
activities may present a feasible alternative to antibiotic growth promoters in animal feed. The free
forms of organic acids may exhibit high potential in the stomach, whereas the ester forms of organic
acids may be able to deliver the benefits to the small intestine of animals. Additionally, it is speculated
that bacteria do not develop resistance to organic acids as they have done to antimicrobial drugs.
However, more research must be conducted to confirm this speculation. More in vivo research in
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livestock animals is necessary to test the efficacy of these in vitro effective organic acid derivatives as
alternatives to antibiotics in feed.
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